Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 22,371 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Clear all
Recruiting No phase listed Observational

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

NCT06784167
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Primary Mediastinal Large B-Cell Lymphoma, Small Lymphocytic Lymphoma
Interventions
Non-Interventional Study
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 29, 2026, 11:03 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evaluating the Impact of Incentives on Clinical Trial Participation

NCT04809636
View directory record Official record
Conditions
Hiv, Aging, Incentives
Interventions
This is not an interventional study
Other
Lead sponsor
University of California, Riverside
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 29, 2026, 11:03 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02734771
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Brentuximab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
Drug
Lead sponsor
Patrick Reagan
Other
Eligibility
75 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Rochester, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 29, 2026, 11:03 AM EDT
Withdrawn Phase 2 Interventional

Early Intervention With Acalabrutinib in Patients With High Risk CLL

NCT04660045
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, CLL/SLL
Interventions
Acalabrutinib
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 4 Interventional Results available

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)

NCT01102972
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Reyataz + Norvir + Truvada, Reyataz + Epzicom
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
44
States / cities
Hobson City, Alabama • Phoenix, Arizona • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 29, 2026, 11:03 AM EDT
Terminated Phase 2 Interventional

Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.

NCT00040157
View directory record Official record
Conditions
HIV Infections
Interventions
ACH126-443 (Beta-L-Fd4C)
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 29, 2026, 11:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes

NCT05626712
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes Mellitus, Type 1
Interventions
CELZ-201 Administration, Control Group
Biological · Other
Lead sponsor
Creative Medical Technology Holdings Inc
Industry
Eligibility
18 Years to 35 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 29, 2026, 11:03 AM EDT
Not listed No phase listed Observational

Molecular and Clinical Studies of Primary Immunodeficiency Diseases

NCT00006319
View directory record Official record
Conditions
Wiskott- Aldrich Syndrome, ADA Deficient SCID
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
3 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 1 Interventional

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT02199665
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
selinexor, carfilzomib, dexamethasone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
5
States / cities
Scottsdale, Arizona • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

ATG-GCSF in New Onset Type 1 Diabetes

NCT02215200
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
13
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Not applicable Interventional Results available

Project to Improve Communication About Serious Illness - Pilot Study

NCT03746392
View directory record Official record
Conditions
Malignant Neoplasm, Leukemia, Lymphocytic, Chronic, B-Cell, Lung Disease Chronic, Congestive Heart Failure, Liver Failures, Chronic, Renal Insufficiency, Chronic, Dementia, Diabetes Complications, Peripheral Vascular Disease, Frail Elderly
Interventions
Jumpstart Intervention
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 29, 2026, 11:03 AM EDT
Terminated Phase 1 Interventional

Islet Cell Transplants for Diabetes

NCT00303134
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet Cell Transplantation
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 29, 2026, 11:03 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

MyPEEPS LITE Trial

NCT06741631
View directory record Official record
Conditions
HIV/AIDS
Interventions
MyPEEPS Mobile
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
16 Years to 29 Years · Male only
Enrollment
3,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS

NCT00002331
View directory record Official record
Conditions
Mycobacterium Avium-intracellular Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Clarithromycin, Clofazimine
Drug
Lead sponsor
Abbott
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1995
U.S. locations
17
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 4 Interventional

DHFS for Medication Adherence Support During Hospital Admissions for Person Living With HIV

NCT04418037
View directory record Official record
Conditions
HIV/AIDS
Interventions
Digital Health Feedback System(DHFS)
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 2 Interventional

Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients

NCT00001357
View directory record Official record
Conditions
HIV Infection
Interventions
Interleukin-2
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 1Phase 2 Interventional

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

NCT00048412
View directory record Official record
Conditions
Myelodysplastic Disorders, Leukemia, Multiple Myeloma, Plasma Cell Dyscrasia, Lymphoproliferative Disorders
Interventions
FLUDARABINE, CAMPATH 1H, FK50, Stem Cell Collection and Infusion
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 29, 2026, 11:03 AM EDT
Withdrawn Phase 3 Interventional

Atacicept in Subjects With Active Lupus Nephritis (COMPASS)

NCT05609812
View directory record Official record
Conditions
Lupus Nephritis (LN)
Interventions
Atacicept, Placebo
Drug
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
26
States / cities
Huntsville, Alabama • La Jolla, California • La Palma, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

NCT03202628
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Pomalidomide
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

NCT03012165
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
ADX-102 Ophthalmic Drops (0.5%), ADX-102 Ophthalmic Drops (0.1%), Vehicle of ADX-102 Ophthalmic Drops
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Morrow, Georgia • Kansas City, Missouri • Mason, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 3 Interventional

BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient

NCT05322707
View directory record Official record
Conditions
Asthma
Interventions
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg, Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol, Placebo
Drug
Lead sponsor
Cipla Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes

NCT00116207
View directory record Official record
Conditions
Diabetic Autonomic Neuropathy
Interventions
ORAL ANTIOXIDANT
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 29, 2026, 11:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Peripheral Blood Stem Cells Obtained From Normal Volunteers for Studying Retroviral Vector Mediated Gene Transfer Into Primitive Hematopoietic Cells and Vector Mediated Transgene Expression in Mature Hematopoietic Lineages

NCT00758992
View directory record Official record
Conditions
Immunodeficiency
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma

NCT02078102
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin's Lymphoma
Interventions
Meloxicam, Filgrastim
Drug
Lead sponsor
Sherif S. Farag
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 29, 2026, 11:03 AM EDT